Sylvester Comprehensive Cancer Center

  • ATA 129-EAP-901 - Beitinjaneh, Amer

  • Investigator:
    Amer Beitinjaneh
    RCname Email

    Coordinator:

    IRB: 20190076

    SDG: Leukemia, Lymphoma, and Myeloma
    Disease Site(s):

    Non-Hodgkin Lymphoma

    Sponsor: Atara

    Enrolling Sites:

    Sylvester

    Title:

    Expanded Access Protocol for Providing Tabelecleucel to Patients with Epstein-Barr Virus-Associated Viremia or Malignancies for Whom there are No Appropriate Alternative Therapies

    Eligibility Criteria - NCT02822495 *This information has been extracted from " www.clinicaltrials.gov"

  • TAPUR - Calfa, Carmen

  • Investigator:
    Carmen Calfa
    RCname Email

    Coordinator:
    RCemailImg Carolina Troche
    RCphone +1 (305) 2431481

    IRB: 20170529

    SDG: Breast Cancer
    Disease Site(s):

    Breast,Colon,Kaposis sarcoma,Kidney,Larynx,Liver,Lymphoid Leukemia,Multiple,Multiple Myeloma,Non-Hodgkin Lymphoma,Pancreas,Prostate,Soft Tissue

    Sponsor: ASCO

    Enrolling Sites:

    Aventura
    Deerfield
    Gables
    Kendall
    Plantation
    Sylvester

    Title:

    The Targeted Agent and Profiling Utilization Registry (TAPUR) Study

    Eligibility Criteria - NCT02693535 *This information has been extracted from " www.clinicaltrials.gov"

  • 20210406 - Camargo Galvis Jose

  • Investigator:
    Jose Camargo Galvis
    RCname Email

    Coordinator:

    IRB: 20210406

    SDG: Leukemia, Lymphoma, and Myeloma
    Disease Site(s):

    Sponsor: AlloVir Inc

    Enrolling Sites:

    Sylvester
    UMH

    Title:

    Phase 1/2, Double-Blind, Placebo-Controlled, Dose Escalation andExpansion Study of ALVR106 in Addition to Standard of Care forthe Treatment of High-Risk Patients with Respiratory ViralInfections After Hematopoietic Cell Transplant

    Eligibility Criteria - NCT04933968 *This information has been extracted from " www.clinicaltrials.gov"

  • MATCH - Huang, Marilyn

  • Investigator:
    Marilyn Huang
    RCname Email

    Coordinator:
    RCemailImg Carolina Troche
    RCphone +1 (305) 2431481

    IRB: 20150671

    SDG: Gynecologic Cancer
    Disease Site(s):

    Cervix Uteri,Colon,Corpus Uteri,Kaposis sarcoma,Kidney,Larynx,Liver,Multiple Myeloma,Non-Hodgkin Lymphoma,Other Female Genital,Ovary,Pancreas,Prostate,Soft Tissue

    Sponsor: ECOG

    Enrolling Sites:

    Coral Springs
    Deerfield
    Gables
    Hollywood
    Kendall
    Plantation
    Sylvester

    Title:

    Molecular Analysis for Therapy Choice (MATCH)

    Eligibility Criteria - NCT02465060 *This information has been extracted from " www.clinicaltrials.gov"

  • Zuma 9 - Lekakis, Lazaros

  • Investigator:
    Lazaros Lekakis
    RCname Email

    Coordinator:

    IRB: 20181106

    SDG: Leukemia, Lymphoma, and Myeloma
    Disease Site(s):

    Non-Hodgkin Lymphoma

    Sponsor: Kite

    Enrolling Sites:

    Sylvester

    Title:

    A Multicenter, Open-Label, Expanded Access Study of Axicabtagene Ciloleucel for the Treatment of Subjects with Relapsed/Refractory Large B-Cell Lymphoma

    Eligibility Criteria - NCT03153462 *This information has been extracted from " www.clinicaltrials.gov"

  • 20191190 - Lekakis Lazaros

  • Investigator:
    Lazaros Lekakis
    RCname Email

    Coordinator:

    IRB: 20191190

    SDG: Leukemia, Lymphoma, and Myeloma
    Disease Site(s):

    Hodgkin Lymphoma,Leukemia, Other,Leukemia, not otherwise specified,Lymphoid Leukemia,Multiple Myeloma,Myeloid and Monocytic Leukemia,Non-Hodgkin Lymphoma,Other Hematopoietic

    Sponsor: Incyte Corporation

    Enrolling Sites:

    Sylvester

    Title:

    A Phase 2 study of Itacitinib for the Prevention of Cytokine Release Syndrome Induced by Immune Effector Cell Therapy

    Eligibility Criteria - NCT04071366 *This information has been extracted from " www.clinicaltrials.gov"

  • GO40515 - Lossos, Izidore

  • Investigator:
    Izidore Lossos
    RCname Email

    Coordinator:

    IRB: 20180638

    SDG: Lymphoma
    Disease Site(s):

    Non-Hodgkin Lymphoma

    Sponsor: Hoffmann - La Roche

    Enrolling Sites:

    Sylvester

    Title:

    GO40515: A Phase Ib/II, Open-Label, Multicenter, Randomized, Controlled Study Investigating The Safety, Tolerability, Pharmacokinetics, And Efficacy OfMosunetuzumab (BTCT4465) In Combination With CHOP or CHP-PolatuzumabVedotin In Patients With B-Cell Non-Hodgkin Lymphoma

    Eligibility Criteria - NCT03677141 *This information has been extracted from " www.clinicaltrials.gov"

  • CPI-006-001 - Merchan, Jaime

  • Investigator:
    Jaime Merchan
    RCname Email

    Coordinator:
    RCemailImg Rakhi Modak
    RCphone +1 (305) 2437387

    IRB: 20180279

    SDG: Prostate, Bladder, and Kidney Cancers
    Disease Site(s):

    Bladder,Bones and Joints,Cervix Uteri,Colon,Corpus Uteri,Kidney,Lip, Oral Cavity and Pharynx,Lung,Lymphoid Leukemia,Non-Hodgkin Lymphoma,Pancreas,Prostate,Rectum,Soft Tissue

    Sponsor: CP

    Enrolling Sites:

    Sylvester

    Title:

    CPI-006-001: A Phase 1/1b Multicenter Study To Evaluate The Humanized Anti-CD 73 Antibody, CPI-006, As A Single Agent, In Combination WIith CPI-444, And In Combination With Pembrolizumab In Adult Subjects With Advanced Cancers

    Eligibility Criteria - NCT03454451 *This information has been extracted from " www.clinicaltrials.gov"

  • 20201285 - Pereira Denise

  • Investigator:
    Denise Pereira
    RCname Email

    Coordinator:

    IRB: 20201285

    SDG: Leukemia, Lymphoma, and Myeloma
    Disease Site(s):

    Multiple Myeloma

    Sponsor: SWOG

    Enrolling Sites:

    Plantation
    Sylvester

    Title:

    S1803, Phase III Study of Daratumumab/rHuPH20 (NSC-810307) + Lenalidomide or Lenalidomide as Post-Autologous Stem Cell Transplant Maintenance Therapy in Patients With Multiple Myeloma (MM) Using Minimal Residual Disease to Direct Therapy Duration (DRAMMATIC Study)

    Eligibility Criteria - NCT04071457 *This information has been extracted from " www.clinicaltrials.gov"

  • AMC-095 - Ramos, Juan Carlos

  • Investigator:
    Juan Carlos Ramos
    RCname Email

    Coordinator:

    IRB: 20160656

    SDG: Leukemia, Lymphoma, and Myeloma
    Disease Site(s):

    Anus,Lip, Oral Cavity and Pharynx,Lung,Other Hematopoietic

    Sponsor: AMC

    Enrolling Sites:

    Sylvester

    Title:

    A Phase I Study of Ipilimumab and Nivolumab in Advanced HIV Associated Solid Tumors with an Expansion Cohort in HIV Associated Solid Tumors

    Eligibility Criteria - NCT02408861 *This information has been extracted from " www.clinicaltrials.gov"

  • AMC-101 - Ramos, Juan Carlos

  • Investigator:
    Juan Carlos Ramos
    RCname Email

    Coordinator:

    IRB: 20180056

    SDG: Leukemia, Lymphoma, and Myeloma
    Disease Site(s):

    Non-Hodgkin Lymphoma

    Sponsor: AMC

    Enrolling Sites:

    Sylvester

    Title:

    AMC-101: A Pilot Study of Ibrutinib and R-da-EPOCH for Front Line Treatment of AIDS-Related Lymphomas A Trial of the AIDS Malignancy Consortium (AMC)

    Eligibility Criteria - NCT03220022 *This information has been extracted from " www.clinicaltrials.gov"

  • CCTL019B20031 - Wang, Trent

  • Investigator:
    Trent Wang
    RCname Email

    Coordinator:

    IRB: 20190006

    SDG: Leukemia, Lymphoma, and Myeloma
    Disease Site(s):

    Lymphoid Leukemia,Non-Hodgkin Lymphoma

    Sponsor: NOVARTIS

    Enrolling Sites:

    Sylvester

    Title:

    CCTL019B2003I: Managed Access Program (MAP) to provide access to CTL019, for acute lymphoblastic leukemia (ALL) or large B-cell lymphoma patients with out of specification leukapheresis product and/or manufactured tisagenlecleucel out of specification for commercial release

    Eligibility Criteria - NCT03601442 *This information has been extracted from " www.clinicaltrials.gov"

  • S17-00978 - Watts, Justin

  • Investigator:
    Justin Watts
    RCname Email

    Coordinator:
    RCemailImg Rafael Perez
    RCphone +1 (786) 4245769

    IRB: 20180143

    SDG: Leukemia/heme
    Disease Site(s):

    Leukemia, Other

    Sponsor: NYULMC

    Enrolling Sites:

    Sylvester

    Title:

    S17-00978:A Phase Ib/IIa Study Evaluating the Safety and Tolerability ofVitamin C in Patients with Intermediate or high Risk Myelodysplastic Syndrome with TET2 Mutations

    Eligibility Criteria - NCT03433781 *This information has been extracted from " www.clinicaltrials.gov"